A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Latest Information Update: 15 Mar 2024
Price :
$35 *
At a glance
- Drugs Pamrevlumab (Primary) ; Corticosteroids; Deflazacort
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LELANTOS; LELANTOS-1
- Sponsors FibroGen
- 04 Feb 2024 This trial has been discontinued in Italy(global end of the trial 2023-08-17 ),According to European Clinical Trials Database Record
- 10 Oct 2023 This study has been completed in USA, According to European Clinical Trials Database Record.
- 27 Sep 2023 Status changed from active, no longer recruiting to discontinued.